U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H22Cl2N2O
Molecular Weight 329.265
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AH-7921

SMILES

CN(C)C2(CNC(=O)C1=CC=C(Cl)C(Cl)=C1)CCCCC2

InChI

InChIKey=JMZROFPPEXCTST-UHFFFAOYSA-N
InChI=1S/C16H22Cl2N2O/c1-20(2)16(8-4-3-5-9-16)11-19-15(21)12-6-7-13(17)14(18)10-12/h6-7,10H,3-5,8-9,11H2,1-2H3,(H,19,21)

HIDE SMILES / InChI

Molecular Formula C16H22Cl2N2O
Molecular Weight 329.265
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/28713291 | https://www.ncbi.nlm.nih.gov/pubmed/26331297 | http://www.emcdda.europa.eu/publications/risk-assessment/AH-7921

AH-7921 (3,4-Dichloro-N-([1-(dimethylamino)cyclohexyl] methyl)benzamide) is an N-substituted cyclohexylmethylbenzamide classified as an opioid analgesic with high addictive liability. The compound acts as an agonist of μ-opioid receptors, although at high doses it can also stimulate κ-opioid receptors. In animal studies, AH-7921 produced typical morphine-like actions, i.e., antinociception, respiratory depression, sedation, miosis, inhibition of gut propulsion, and lowered body temperature, with a potency almost equipotent to that of morphine. There is limited information available on the routes of administration and the doses of AH-7921 used. The compound is taken orally, nasally, by smoking, and, less commonly, by intravenous injection. Minimal oral effective doses for complete pain suppression by AH 7921 are 1.25 and 13.8 mg/kg for canine and rhesus monkey, respectively.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Light dose is 5-10 mg, common dose is 10–25 mg and strong dose is over 25 mg.
Route of Administration: Oral
For metabolic stability, 1 μmol/L AH-7921 was incubated with human liver microsome (HLM) for up to 1 h, for metabolite profiling, 10 μmol/L was incubated with pooled human hepatocytes for up to 3 h. Hepatocyte samples were analyzed by liquid chromatography quadrupole/time-of-flight high-resolution mass spectrometry. AH-7921 in vitro half-life was 13.5±0.4 min.
Substance Class Chemical
Created
by admin
on Thu Jul 06 16:38:28 UTC 2023
Edited
by admin
on Thu Jul 06 16:38:28 UTC 2023
Record UNII
10BR7A0SO0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AH-7921
Code English
3,4-DICHLORO-N-((1-(DIMETHYLAMINO)CYCLOHEXYL)METHYL)BENZAMIDE
Systematic Name English
J326.187E
Code English
AH 7921
Code English
BENZAMIDE, 3,4-DICHLORO-N-((1-(DIMETHYLAMINO)CYCLOHEXYL)METHYL)-
Systematic Name English
3,4-dichloro-N-((1-(dimethylamino)cyclohexyl)methyl)benzamide [WHO-DD]
Common Name English
Classification Tree Code System Code
WIKIPEDIA Designer-drugs-AH-7921
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
DEA NO. 9551
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID70203662
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
PRIMARY
CAS
55154-30-8
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
PRIMARY
SMS_ID
100000175496
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
PRIMARY
PUBCHEM
187760
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
PRIMARY
WIKIPEDIA
AH-7921
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
PRIMARY
FDA UNII
10BR7A0SO0
Created by admin on Thu Jul 06 16:38:28 UTC 2023 , Edited by admin on Thu Jul 06 16:38:28 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY